- Home
- PHAR
PHAR
Pharming Group N.V.
as 06-20-2025 4:00pm EST
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
| Founded: | 1988 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 718.1M | IPO Year: | N/A |
| Target Price: | $30.00 | AVG Volume (30 days): | 2.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.65 - $12.61 | Next Earning Date: | 07-31-2025 |
| Revenue: | $320,708,000 | Revenue Growth: | 24.13% |
| Revenue Growth (this year): | 13.31% | Revenue Growth (next year): | 7.68% |
Latest Pharming Group N.V. News
PHAR Breaking Stock News: Dive into PHAR Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
European Penny Stocks Under €200M Market Cap To Watch
GlobeNewswire
10 days ago
Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders
GlobeNewswire
24 days ago
Pharming Group to participate in June investor conferences
Simply Wall St.
a month ago
European Penny Stocks To Watch In May 2025
Simply Wall St.
a month ago
High Growth Tech Stocks In Europe Featuring Three Promising Picks
Simply Wall St.
a month ago
Pharming Group First Quarter 2025 Earnings: US$0.022 loss per share (vs US$0.019 loss in 1Q 2024)
GuruFocus.com
a month ago
Pharming Group (PHGUF) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth ...
GlobeNewswire
a month ago
Pharming Group reports first quarter 2025 financial results and provides business update
Compare PHAR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHAR Pharming Group N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.